focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Link to the drive page
https://drive.hhs.gov/host_tx.html
Very Synergistic language. If Casanova are looking to test their assay and J&J are looking for partnerships then both can see an interest from Barda if they can find an antiviral that’s virus agnostic and uses patient stratification.
Also of interest given Synairgens approach and covered in the Drive program Host Directed Therapies is the last paragraph on Patient stratification.
Our current areas of HDT focus include:
Interventions to prevent or reduce infection progression to severe outcomes
Therapies that improve long term outcomes and prevent health deterioration
Patient stratification to subtype populations for improved clinical management
Https://medicalcountermeasures.gov/newsroom/2024/hdt/
The first paragraph could have been written by Synairgen
“There are currently no host-directed, pathogen-agnostic products approved by the U.S. Food and Drug Administration (FDA) for treating severe outcomes of infectious disease”
We’ve discussed before but worth reminding everyone.
Thanks to a poster in another place for reminding me of the link
It’s clear that Synairgen only update the market when they have substantial news. We may not like it but that’s what they do.
I have two choices
I can endlessly and almost daily, moan about it. Which clearly isn’t going to change anything.
Or
I can be patient, understand trials are complex with many moving parts, most of which Synairgen do not control and focus on the positives.
One of these choices will drag you down, the other will give you hope
Everyone has to choose their own path.
Despite the delays. Despite the lack of news
There’s a lot to remain positive about
IFN-β alleviates virus-induced asthma exacerbations
To evaluate the therapeutic effect of IFN-β on virus-induced asthma exacerbations, we treated asthma exacerbation mice with IFN-β or dexamethasone (Dex) (Fig. 8a). Asthma exacerbation mice showed a remarkable decrease in weight, which was significantly alleviated by IFN-β treatment but not Dex treatment (Fig. 8b). In addition, although the IFN-β treatment and Dex treatment groups both showed reduced respiratory system resistance and airway resistance in virus-induced asthma exacerbation mice, IFN-β treatment was significantly more effective in preserving the respiratory system compliance and tissue damping and elasticity (Fig. 8c), which indicates that IFN-β treatment not only has an effect on the airways, but also has a good effect of improvement on AHR caused by tissue damage
https://www.nature.com/articles/s41467-023-44168-0
Interesting that the calculation of the companies worth starts from multiples of 6p.
I wonder what it will be once trials start or the first hint of P2’s. I seem to recall it dropped in minutes after Sprinter. How long will a climb take on positive news.
The true value of this company has nothing to do with multiples of 6p in my view and everything to do with the results from P2’s, the perceived market size and how many companies are interested.
Great game, but before Spacman turns up to ask how much Tommy thinks it’s worth. Let’s just wait and see.
Oh and Professional, Ghia it’s highly amusing that you think I’m sitting on huge losses but I’ve had 2 years of buying at pennies so keep on dreaming the dream.
Https://www.sciencedirect.com/science/article/abs/pii/S1044532324000010
Interestingly, autoantibodies neutralizing type I IFNs were also found to underlie over 20% of breakthrough cases of COVID-19 hypoxemic pneumonia in already vaccinated individuals, highlighting the major importance type I IFNs and innate immunity
The answer in my view is very simple. It is highly unlikely that anyone will offer a significant amount for this company knowing a further investment of 10’s to 100’s of millions may be required to put the product through commercialisation until they have a reasonable expectation through P2’s that their investment risk is well founded.
Perhaps a BP might as it’s a field they understand and in the great scheme of things to BP it’s peanuts.
But right now they either don’t need to or (hopefully this is not the case) they’re just not that interested.
Only time will tell but I would suggest that things will hot up when the first results start to appear from the P2’s and if there is any sense that they look good the price of this share has the same ability to climb as it did to fall.
Spacman
It seems your belief in this companies value is rapidly going south from 600m to 200m
We know no one needs the boards permission to put forward an offer so if TFG will accept 200m and we know Doc D will accept 40p so he’d snap their hands off at 200m. Why isn’t the offer on the table right now. The board can’t stop it being put to shareholders!
Considering people who know you tell me you’re a man of finance Spacman. You do put forward some strange ideas.
We all know the company does not need a for sale sign. Anyone even Professional could offer to buy the company on Monday for 5, 50 or 500 million. They don’t require a for sale sign.
It’s clear if such a buyer exists they have not been given the blessing of the board or its largest investor that making an offer would succeed at this point.
But if you believe what you keep telling us that the company must be worth 600m. Get some friends together and make the offer and we can all vote on it.
Do we all not think the for sale sign has always been up on the front lawn?
I know I’ve always assumed the for sale is 10’ high with neon lights shouting buy us!
It seems obvious that no one is prepared offer what the board and I assume our largest shareholder thought the company was worth prior to Sprinter otherwise we’d have had an offer.
Fwiw the companies true value rests on the P2’s in my view. There is zero point in accepting an offer as long as we can finance those trials and wait for the results.
The board would not be serving its shareholders to try to sell the company at this point unless an offer realistically valued it or the finances left them with no alternative.
Clearly the board and our biggest shareholder don’t believe such an offer exists or that we are in that situation or they would have acted.
It’s been clear for some time from the information provided at the AGM and the interim results that the company sees multiple pathways in its future. The precise nature will no doubt be part of non disclosure agreements, trading rules and negotiations with partners.. But these potential pathways have been clearly established for sometime.
The company needs to prove the effectiveness of the drug in the right patient population via its new studies in H1.
Subject to that outcome the company will pursue registration of the drug through a P3.
That route could involve private investors, shareholders or BP and may result in the licensing of the drug in part to different BP for different diseases or as a whole broad spectrum offering.
The key here is that none of that is likely to happen until the trials provide the required outcome.
So will we get a further more detailed understanding other than the broad concepts above in the next period? In my view we will not. We will only get that kind of update when the board has negotiated a route to P3 along with finances and which route or routes will be dictated by the offers available to them at the time.
It will certainly not be forthcoming except in the broad terms we already understand in my view.
21 Sept
Operational
· Progressing the Company's patient identification strategy through biomarker and existing clinical data analysis. This will enable the Company to identify patients at higher risk of disease progression, including those with deficient innate immune response and/or high viral load, who might therefore be more likely to respond to SNG001 in future clinical studies.
· Conducting non-interventional preparatory work to expand hospitalised patient populations for potential treatment with SNG001, which are likely to include: ventilated patients with confirmed viral pneumonia; and patients who are unable to clear virus and become persistent viral "shedders", a majority of whom are immunocompromised. Subject to this preparatory work and regulatory approval timelines, trials are anticipated to start in H1 2024.
· Insights from non-interventional studies and the substantial body of evidence gathered to date from previous clinical trials will inform a robust clinical programme for the development of SNG001.
Fruits you are wasting your time with this individual.
He talks about bad feeling on this board. But he’s one of the key instigators and clearly lives for creating it.
“ you too are at the bookies with your little stubby pencils”
“That sounds more like a pi talking to fellow pis and less like Moses returning from Mount Sinai bearing the word of God”
Doc D
Below is what I said on January 24th
That is somewhat different than your assertion (blatant misrepresentation) of what I said.
No one can say we will get an update. They can only give a view and a reasoning for that view. If they’re sensible they will reset that expectation following new information.
You seem to think today’s email isn’t new information. I think it offers clues as to when we are likely to get an update. Please note the word “likely” it doesn’t mean we will and it doesn’t mean we will have to wait until Apr - May it’s just my thoughts !!
January 24th post
“I remain of the view that towards end of next month we will have a clearer idea and I’m happy to wait. If the share price drifts I see it as another opportunity to buy because news will likely create an uplift from the current price.”
Move on from your unnecessary nonsense intervention
Doc D
I see that you’re back to your boring Yobish insults creating rows where none are required.
The company quoted H1 for trials. To be it seemed likely we would not therefore get news in Q1
Now we have an update mentioning Q2 and full year results. To me it seems likely I need to reset my expectations to full year results which are normally Apr- May.
If you have a different view that you can explain without responding like a 3 year old feel free to comment.